Warfarin, not direct oral anticoagulants nor antiplatelet therapy, is associated with increased bleeding risk in emergency general surgery patients: implications in this new era of novel anticoagulants: An EAST Multicenter study.
Seema P AnandalwarLindsay O'MearaRoumen VesselinovAshling ZhangJeffrey N BaumAmanda CooperCassandra DeckerThomas SchroeppelJenny CaiDaniel CullinaneRichard D CatalanoNikolay BugaevMadison LeClairChristina FeatherKatherine McBrideValerie SamsPak Shan LeungSamantha OlafsonDevon S CallahanJoseph PoslusznySimon MoradianJordan EstroffBeth HochmanNatasha ColemanAnna Goldenberg-SandauJeffry NahmiasKathryn RosenbaumJason PasleyLindsay BollLeah HustadJessica ReynoldsMichael TruittMira GhneimPublished in: The journal of trauma and acute care surgery (2024)
Despite ongoing concerns about the increase in DOAC use & lack of readily available reversal agents, this study suggests that warfarin, rather than DOACs, is associated with higher perioperative bleeding complications. However, that risk does not result in an increase in mortality, suggesting that perioperative decisions should be dictated by patient disease & comorbidities rather than type of antiplatelet or anticoagulant use.
Keyphrases
- direct oral anticoagulants
- atrial fibrillation
- venous thromboembolism
- antiplatelet therapy
- percutaneous coronary intervention
- acute coronary syndrome
- end stage renal disease
- cardiac surgery
- patients undergoing
- oral anticoagulants
- ejection fraction
- newly diagnosed
- chronic kidney disease
- emergency department
- healthcare
- risk factors
- case report
- prognostic factors
- patient reported outcomes
- patient reported